Navigation Links
Novavax Reports Fourth Quarter and 2008 Year-End Financial Results
Date:3/31/2009

li>
  • The Company took significant measures, including a reduction in force early this year, to reduce its expenses and thereby the yearly burn rate.

  • "We made significant progress in 2008 in advancing our VLP based vaccine pipeline. We demonstrated in Phase II clinical studies that our VLP based flu vaccines are not only well tolerated and immunogenic in humans, but they have the potential to differentiate themselves from currently available alternatives. We also demonstrated that our VLP technology has the potential to create a much needed vaccine against RSV. These advances continue to reinforce that our strategy of using the VLP vaccine platform coupled with our innovative manufacturing solution is working," said Novavax Chief Executive Officer Dr. Rahul Singhvi. "By the second half of 2009, we want to translate these scientific advances into partnerships with private and public entities to leverage capabilities of our partners to accelerate our progress, as we have shown today with the Cadila partnership."

    2008 Financial Results

    Revenue from continuing operations, for the fourth quarter ended December 31, 2008, related to the government contracts was $100,000 compared to $400,000 for the same period in 2007. Revenue for the full year of 2008 was $1.1 million as compared to $1.5 million in 2007. The reduction in our revenue was due to the timing of our completing these contracts.

    Research and development costs for the fourth quarter of 2008 were $5.9 million compared to $4.2 million in the fourth quarter of 2007. For the full year, research and development costs increased 38 percent to $24.3 million in 2008 from $17.6 million in 2007. The increases in both the fourth quarter of 2008 and the year ended December 31, 2008 compared to 2007 were due to higher research and development spending to support the Company's strategic focus on creating d
    '/>"/>

    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine news :

    1. Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call
    2. Novavax CEO to Present at the Partnering for Global Health Forum
    3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
    4. Novavax Announces Release Date of 2007 Third Quarter Financial Results and Investor Conference Call
    5. Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb
    6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
    7. Cadus Reports 2008 Results
    8. Nephros Reports 2008 Fourth Quarter and Full Year Financial Results
    9. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
    10. Tiens Biotech Group (USA) Reports Record Twelve-Month Results
    11. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
    (Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
    (Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
    (Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
    (Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
    Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
    ... 6 percent of U.S. hospital emergency departments are fully ... of novel H1N1 (swine) flu expected this winter, the ... In a joint policy statement published in Pediatrics ... Department," pediatric emergency medicine specialists and others provide recommendations ...
    ... Federal stimulus funding is helping a Kansas State University ... Their research is creating a clearer picture of a ... chronic diseases like cancer. Katsura Asano, K-State associate ... from the National Institutes of Health,s National Institute of ...
    ... so-called junk DNA to be cut and pasted within genetic ... therapies. The study by researchers at the University of ... in which shifted genes have a significant effect on the ... antibody genes can enable the immune system to target infection ...
    ... NEW YORK, Sept. 21 Within the first three seconds ... in many first encounters, from the first day of school to the ... help you exude confidence, so follow these helpful tips to get yourself ... go to: http://www.prnewswire.com/mnr/crest/39172/ , , ...
    ... INDIANAPOLIS, Sept. 21 Eli Lilly and Company ... on the Human Rights Campaign,s (HRC) Corporate Equality Index for 2010. ... the Best Places to Work for Lesbian, Gay, Bisexual, and Transgender (LGBT) ... organization,s efforts related to creating an equitable environment for lesbian, gay, bisexual, ...
    ... , , ABBOTT PARK, Ill., Sept. 21 ... from the U.S. Food and Drug Administration (FDA) for its ABBOTT PRISM ... HIV-1/HIV-2. This test can be used by laboratory professionals to screen ... type 1 Groups M and O (anti-HIV-1) and type 2 (anti-HIV-2), and ...
    Cached Medicine News:Health News:Photos: Fall's First Impressions 2Health News:Lilly Receives 100 Percent Rating on Corporate Equality Index Survey 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 3
    (Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
    (Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
    (Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
    Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4
    ... May 20 Despite concerns from public health officials, influenza ... to a new analysis presented recently at the Academy of Managed Care ... (Prime), a thought leader in pharmacy benefit management. , ... For the study, researchers from Prime and ...
    ... Today, in a world first, Asda announces a commitment ... ,not for profit, basis potentially saving thousands of pounds for sufferers. ... UK and as part of Asda,s ,not for profit, commitment it ... cancer, is now available for 2,167.71 pounds Sterling compared ...
    Cached Medicine Technology:New Prime Therapeutics Study Finds Antiviral Medications Were Not Hoarded During H1N1 Flu Season 2In a World First, Asda Announces 'Not for Profit' Price on All Cancer Treatment Drugs 2In a World First, Asda Announces 'Not for Profit' Price on All Cancer Treatment Drugs 3
    ... In the specialty areas of ... intensive care work, it is ... your practice. Alokas motorized TEE ... and Tissue Harmonic Echo technology ...
    Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
    ... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
    ... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
    Medicine Products: